Home/Filings/4/0001218629-26-000002
4//SEC Filing

SCHLEIFER LEONARD S 4

Accession 0001218629-26-000002

CIK 0000872589other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 5:53 PM ET

Size

11.2 KB

Accession

0001218629-26-000002

Insider Transaction Report

Form 4
Period: 2025-12-31
SCHLEIFER LEONARD S
DirectorCEO and President10% Owner
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-31+28,570243,093 total
  • Tax Payment

    Common Stock

    2025-12-31$772.09/sh28,570$22,058,611214,523 total
  • Exercise/Conversion

    2020 Performance Stock Units

    2025-12-3128,570595,077 total
    Common Stock (28,570 underlying)
Holdings
  • Common Stock

    (indirect: By 2024 GRAT)
    127,484
  • Common Stock

    (indirect: By 2025 GRAT)
    300,000
  • Common Stock

    (indirect: By 401(k))
    5,989
  • Common Stock

    (indirect: By Trust)
    39,985
Footnotes (1)
  • [F1]Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.

Issuer

REGENERON PHARMACEUTICALS, INC.

CIK 0000872589

Entity typeother

Related Parties

1
  • filerCIK 0001218629

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 5:53 PM ET
Size
11.2 KB